VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Blueprint Medicines Executive Compensation (FY24)

BPMC · Executive and director compensation, fiscal 2022 to 2024
Chief executive, fiscal 2024
◇
Kathryn Haviland
Latest say-on-pay support
=
June 18, 2025
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Blueprint Medicines brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 4, 2026Latest filing (8-K): June 20, 2025
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Blueprint Medicines brief$500Get the executive brief
Velarion Intel, one year, every company
341 figures on this page: 333 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kathryn Haviland: $6,432,012 → $13,477,004 (109.5% higher)
CEO pay ratio: 20:1 → 35:1 (75.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Blueprint Medicines' chief executive and what were they paid?
Kathryn Haviland was paid $13,477,004 in total compensation as President and Chief Executive Officer for fiscal 2024. Compared with the $6,432,012 reported for fiscal 2023, Haviland's total was 109.5% higher.
What was Blueprint Medicines' say-on-pay result?
Shareholders recorded 95.9% support for the say-on-pay proposal at the meeting held June 18, 2025 for fiscal 2024.
Which companies are in Blueprint Medicines' peer group?
Companies named in the disclosed peer group include ACADIA Pharmaceuticals Inc., Agios Pharmaceuticals, Inc., Alkermes, Inc., Amicus Therapeutics, Inc. and Apellis Pharmaceuticals, Inc., among others.
What is Blueprint Medicines' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2024 is 35:1, against median employee compensation of $389,871.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kathryn Haviland
President and Chief Executive Officer
◇—◇◇◇—◇◇
Fouad Namouni
President, Research and Development
◇—◇◇◇——◇
Christina Rossi
Chief Operating Officer
◇—◇◇◇—◇◇
Michael Landsittel
Chief Financial Officer
◇—◇◇◇—◇◇
Percy Carter
Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kathryn Haviland
President and Chief Executive Officer
◇—◇◇◇—◇◇
Christina Rossi
Chief Operating Officer
◇—◇◇◇—◇◇
Fouad Namouni
President, Research and Development
◇—◇◇◇—◇◇
Percy Carter
Chief Scientific Officer
◇—◇◇◇—◇◇
Michael Landsittel
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kathryn Haviland
President and Chief Executive Officer
◇—◇◇◇—◇◇
Christina Rossi
Chief Operating Officer
◇—◇◇◇—◇◇
Fouad Namouni
President, Research and Development
◇—◇◇◇—◇◇
Percy Carter
Chief Scientific Officer
◇—◇◇◇—◇◇
Michael Landsittel
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christina RossiRSU◇——◇——◇
Christina RossiPSU◇◇◇—◇—◇
Christina RossiRSU◇——◇——◇
Christina RossiOPTION◇——◇—◇◇
Fouad NamouniPSU◇◇◇—◇—◇
Fouad NamouniOPTION◇——◇—◇◇
Fouad NamouniRSU◇——◇——◇
Kathryn HavilandPSU◇◇◇—◇—◇
Kathryn HavilandRSU◇——◇——◇
Kathryn HavilandOPTION◇——◇—◇◇
Michael LandsittelRSU◇——◇——◇
Michael LandsittelPSU◇◇◇—◇—◇
Michael LandsittelOPTION◇——◇—◇◇
Percy H. CarterPSU◇◇◇—◇—◇
Percy H. CarterOPTION◇——◇—◇◇
Percy H. CarterRSU◇——◇——◇
Percy H. CarterRSU◇——◇——◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Kathryn HavilandOption◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇3/1/2032
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2031
Fouad NamouniOption◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇3/1/2031
Christina RossiOption◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇3/1/2031
Percy CarterOption◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
RSU◇◇——
PSU◇◇——
Option◇—◇6/1/2031
RSU◇◇——
PSU◇◇——
Michael LandsittelOption◇—◇3/1/2034
Option◇—◇3/1/2033
RSU◇◇——
RSU◇◇——
Option◇—◇3/1/2032
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇3/1/2031
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Lynn Seely
Lead independent director
◇◇◇———◇
Mark Goldberg
◇◇◇——◇◇
Jeffrey W. Albers
Board chair
◇◇◇———◇
Daniella Beckman
◇◇◇———◇
Lonnel Coats
◇◇◇———◇
Nicholas Lydon
◇◇◇——◇◇
Habib Dable
◇◇◇———◇
Alexis Borisy
◇◇◇———◇
John Tsai
◇◇◇———◇
Kathryn Haviland served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Rsus/Options.
Stock ownership guideline: All of our directors are in compliance with our current stock ownership guidelines. See “Other Compensation Policies and Practices – Stock Ownership Guidelines” for more information.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • ACADIA Pharmaceuticals Inc. ACAD
  • Agios Pharmaceuticals, Inc. AGIO
  • Alkermes, Inc. ALKS
  • Amicus Therapeutics, Inc. FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • BioCryst Pharmaceuticals, Inc. BCRX
  • CRISPR Therapeutics AG CRSP
  • Deciphera Pharmaceuticals, Inc. DCPH
  • Exelixis, Inc. EXEL
  • Halozyme Therapeutics, Inc. HALO
  • Ionis Pharmaceuticals, Inc. IONS
  • Mirati Therapeutics, Inc. MRTX
  • Neurocrine Biosciences, Inc. NBIX
  • PTC Therapeutic PTCT
  • Sarepta Therapeutics, Inc. SRPT
  • Ultragenyx Pharmaceutical Inc. RARE
  • United Therapeutics, Inc. UTHR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2024June 18, 2025=◇◇◇
2023April 25, 2024=◇◇◇
2022June 21, 2023=◇◇◇
2021June 21, 2022=◇◇◇
2020June 2, 2021=◇◇◇
2019June 23, 2020=◇◇◇
2018June 18, 2019=◇◇◇
2017June 20, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Kathryn Haviland (President and Chief Executive Officer), FY2024 total compensation $13,477,004 (base salary $821,363) [exec_comp, SEC accession 0001558370-25-005415, filed 2025-04-24]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Blueprint Medicines files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Blueprint Medicines disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Blueprint Medicines sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Blueprint Medicines' disclosed peer group is defensible, who names Blueprint Medicines back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
341 figures on this page: 333 cited to the filing that reported them, 8 calculated from figures it prints.
333 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001558370-25-008742
  2. 0001558370-25-005415
    2024 Summary Compensation Table · CHIEF EXECUTIVE OFFICER PAY RATIO DISCLOSURE · DIRECTOR COMPENSATION · Outstanding Equity Awards at 2024 Fiscal Year-End · and 1 more section
  3. 0001104659-24-071734
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001104659-23-075235
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001104659-22-074754
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001558370-21-008015
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  7. 0001558370-20-007819
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  8. 0001558370-19-005811
    Item 5.07. Submission of Matters to a Vote of Security Holders.
  9. 0001558370-18-005408
    Item 5.07. Submission of Matters to a Vote of Security Holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Blueprint Medicines executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/BPMC (accessed 2026).
Short form: data: Velarion

The Blueprint Medicines brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Blueprint Medicines and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Blueprint Medicines discloses

The companies named in BPMC's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Agios Pharmaceuticals, Inc.Alkermes, Inc.Amicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.CRISPR Therapeutics AGDeciphera Pharmaceuticals, Inc.Exelixis, Inc.Halozyme Therapeutics, Inc.Ionis Pharmaceuticals, Inc.Mirati Therapeutics, Inc.Neurocrine Biosciences, Inc.PTC TherapeuticSarepta Therapeutics, Inc.Ultragenyx Pharmaceutical Inc.United Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy